ArticleEmerging infectious diseases2021
Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France.
Article in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05568953 (An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity), which is not on this map. Cited by 167 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
Who cites it
167 citing papers in PubMed, 4 syntheses or guidelines pooled it, 259 citations in OpenAlex.
- Impaired serological response to COVID-19 vaccination following anticancer therapy: A systematic review and meta-analysis.Journal of medical virology · 2022Pooled it
- Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis.Annals of clinical and translational neurology · 2022Pooled it
- Pooled it
- Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.Nature communications · 2023Trial
- Trial
- Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months.Frontiers in immunology · 2022Trial
- Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2.The Journal of clinical investigation · 2020Trial
- Integrated Assessment of Humoral and Cellular SARS-CoV-2 Immunity Using ELISA and a Gold Nanoparticle-Based IGRA.International journal of molecular sciences · 2026Article
- Discordant Outcomes of SARS-CoV-2 Exposure in Household Contacts.Clinical immunology communications · 2026Article
- Primary SARS-CoV-2 exposure by vaccination or infection shapes immune responses to omicron variants among a Spanish cohort.Nature communications · 2025Article
- Delayed Cellular Immunity in SARS-CoV-2 Antibody-Non-Responders to COVID-19 Vaccination: Rethinking Post-Vaccine Immune Assessment.Vaccines · 2025Article
- The potential impacts of human genetics on virus emergence.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Longitudinal analysis of humoral and cellular immunity in SARS-CoV-2 exposed families.Scientific reports · 2025Article
- Quantitative Immunoglobulin G and Interferon-Gamma Responses After Different Booster Strategies of CoronaVac and BNT162b2 Vaccines in Türkiye.Infectious diseases & clinical microbiology · 2025Article
- Article
- A systems biology approach to define SARS-CoV-2 correlates of protection.NPJ vaccines · 2025Article
- Article
- Article
- Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection.PloS one · 2025Article
107 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies and T-cell responses against SARS-CoV-2 and human coronavirus (HCoV) 229E and OC43 in 11 SARS-CoV-2 serodiscordant couples in Strausbourg, France, in which 1 partner had evidence of mild coronavirus disease (COVID-19) and in 10 unexposed healthy controls. Patients with confirmed COVID-19 were considered index patients and their partners close contacts. All index patients displayed positive SARS-CoV-2-specific antibody and T-cell responses that lasted up to 102 days after symptom onset. All contacts remained seronegative for SARS-CoV-2; however, 6 reported COVID-19 symptoms within a median of 7 days after their partners, and 4 of those showed a positive SARS-CoV-2-specific T-cell response against 3 or 4 SARS-CoV-2 antigens that lasted up to 93 days after symptom onset. The 11 couples and controls displayed positive T-cell responses against HCoV-229E or HCoV-OC43. These data suggest that exposure to SARS-CoV-2 can induce virus-specific T-cell responses without seroconversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.